10x Genomics Stock Price, News & Analysis (NASDAQ:TXG) $43.64 +1.48 (+3.51%) (As of 01:34 PM ET) Add Compare Share Share Today's Range$42.71▼$44.7550-Day Range$34.32▼$45.4452-Week Range$31.28▼$63.57Volume607,138 shsAverage Volume964,983 shsMarket Capitalization$5.16 billionP/E RatioN/ADividend YieldN/APrice Target$60.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability 10x Genomics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside40.4% Upside$60.78 Price TargetShort InterestHealthy4.81% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment-0.28Based on 17 Articles This WeekInsider TradingSelling Shares$1.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.84) to ($1.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector429th out of 949 stocksAnalytical Instruments Industry13th out of 29 stocks 3.4 Analyst's Opinion Consensus Rating10x Genomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.78, 10x Genomics has a forecasted upside of 40.4% from its current price of $43.30.Amount of Analyst Coverage10x Genomics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.81% of the outstanding shares of 10x Genomics have been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in 10x Genomics has recently decreased by 15.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) Score10x Genomics has received a 76.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "Microfluidic biochips", and "Workflow automation software for clinical laboratories" products. See details.Environmental SustainabilityThe Environmental Impact score for 10x Genomics is -0.73. Previous Next 1.0 News and Social Media Coverage News Sentiment10x Genomics has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for 10x Genomics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,267,546.00 in company stock.Percentage Held by Insiders10.65% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.16% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($1.84) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -22.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -22.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 10x Genomics Stock (NASDAQ:TXG)10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Read More TXG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TXG Stock News HeadlinesNovember 29, 2023 | tmcnet.comBioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial OfficerNovember 28, 2023 | americanbankingnews.com10x Genomics, Inc. (NASDAQ:TXG) CFO Sells $72,767.86 in StockNovember 29, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 28, 2023 | americanbankingnews.comInsider Selling: 10x Genomics, Inc. (NASDAQ:TXG) CEO Sells 3,757 Shares of StockNovember 28, 2023 | americanbankingnews.comSerge Saxonov Sells 3,723 Shares of 10x Genomics, Inc. (NASDAQ:TXG) StockNovember 28, 2023 | americanbankingnews.comInsider Selling: 10x Genomics, Inc. (NASDAQ:TXG) Insider Sells 3,464 Shares of StockNovember 27, 2023 | msn.comJP Morgan downgrades NanoString to neutral over patent litigationNovember 27, 2023 | americanbankingnews.com10x Genomics, Inc. (NASDAQ:TXG) Receives Average Rating of "Moderate Buy" from AnalystsNovember 29, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 25, 2023 | americanbankingnews.comReviewing 10x Genomics (NASDAQ:TXG) and Revvity (NYSE:RVTY)November 24, 2023 | americanbankingnews.com10x Genomics, Inc. (NASDAQ:TXG) Insider Sells $619,480.62 in StockNovember 23, 2023 | benzinga.comChief Commercial Officer of 10x Genomics Sold $619K In StockNovember 23, 2023 | finance.yahoo.comInsider Sell Alert: Chief Commercial Officer James Wilbur Sells Shares of 10x Genomics IncNovember 20, 2023 | msn.comNanoString falls as company pulls guidance after patent setbackNovember 20, 2023 | benzinga.comWhy Is Life Science Company NanoString Stock Trading Lower Today?November 19, 2023 | finance.yahoo.comHarvard University Stocks List: Top 12 PicksNovember 17, 2023 | finance.yahoo.com10x Genomics Wins Another Patent Infringement Case Against NanoString TechnologiesNovember 9, 2023 | finance.yahoo.comHere’s Why You Should Invest in 10x Genomics (TXG)November 4, 2023 | markets.businessinsider.comSell Rating on 10x Genomics: Analysis of Q3 Performance and Future Growth ConcernsNovember 4, 2023 | seekingalpha.com10x Genomics: Unveiling The Investment PotentialNovember 3, 2023 | markets.businessinsider.com10x Genomics Outperforms Expectations: Xenium Segment Fuels Growth Amid Revised Revenue GuidanceNovember 3, 2023 | finance.yahoo.comQ3 2023 10X Genomics Inc Earnings CallNovember 3, 2023 | finance.yahoo.com10x Genomics, Inc. (NASDAQ:TXG) Q3 2023 Earnings Call TranscriptNovember 3, 2023 | msn.com10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesNovember 2, 2023 | finance.yahoo.com10x Genomics Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.com10x Genomics Inc (TXG) Reports 17% Revenue Increase in Q3 2023November 1, 2023 | finance.yahoo.com10x Genomics to Present at the Stephens 25th Annual ConferenceSee More Headlines Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TXG CUSIPN/A CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,243Year FoundedN/APrice Target and Rating Average Stock Price Target$60.78 High Stock Price Target$75.00 Low Stock Price Target$47.00 Potential Upside/Downside+44.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-166,000,000.00 Net Margins-37.79% Pretax Margin-36.99% Return on Equity-24.24% Return on Assets-19.16% Debt Debt-to-Equity RatioN/A Current Ratio5.37 Quick Ratio4.60 Sales & Book Value Annual Sales$516.41 million Price / Sales9.65 Cash FlowN/A Price / Cash FlowN/A Book Value$6.99 per share Price / Book6.03Miscellaneous Outstanding Shares118,210,000Free Float105,620,000Market Cap$4.98 billion OptionableOptionable Beta1.84 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Serge Saxonov Ph.D. (Age 46)Co-Founder, CEO & Director Comp: $837.68kDr. Benjamin J. Hindson Ph.D. (Age 48)Co-Founder, President, Chief Scientific Officer & Director Comp: $615.96kMr. Justin J. McAnear (Age 47)Chief Financial Officer Comp: $535.91kMr. Eric S. Whitaker Esq. (Age 56)Chief Legal Officer Comp: $558.97kMr. James L. Wilbur Ph.D. (Age 58)Chief Commercial Officer Comp: $390.78kMr. Michael Schnall-LevinFounding Scientist & CTOMs. Cassie CorneauManager of Investor Relations and Strategic FinanceMs. Rebecca PortChief People OfficerMr. James BryantDirector of LegalMr. Nikhil RaoDirector of Product ManagementMore ExecutivesKey CompetitorsOlink Holding AB (publ)NASDAQ:OLKPacific Biosciences of CaliforniaNASDAQ:PACBBio-Rad LaboratoriesNYSE:BIO.BBio-Rad LaboratoriesNYSE:BIOAvantorNYSE:AVTRView All CompetitorsInsiders & InstitutionsBanque Pictet & Cie SASold 4,237 shares on 11/27/2023Ownership: 0.077%Serge SaxonovSold 3,723 sharesTotal: $162,769.56 ($43.72/share)Serge SaxonovSold 3,757 sharesTotal: $162,828.38 ($43.34/share)Justin J McanearSold 1,679 sharesTotal: $72,767.86 ($43.34/share)James WilburSold 3,464 sharesTotal: $150,129.76 ($43.34/share)View All Insider TransactionsView All Institutional Transactions TXG Stock Analysis - Frequently Asked Questions Should I buy or sell 10x Genomics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TXG shares. View TXG analyst ratings or view top-rated stocks. What is 10x Genomics' stock price target for 2024? 8 analysts have issued 1 year price targets for 10x Genomics' shares. Their TXG share price targets range from $47.00 to $75.00. On average, they anticipate the company's stock price to reach $60.78 in the next year. This suggests a possible upside of 36.4% from the stock's current price. View analysts price targets for TXG or view top-rated stocks among Wall Street analysts. How have TXG shares performed in 2023? 10x Genomics' stock was trading at $36.44 on January 1st, 2023. Since then, TXG shares have increased by 22.3% and is now trading at $44.55. View the best growth stocks for 2023 here. When is 10x Genomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our TXG earnings forecast. How were 10x Genomics' earnings last quarter? 10x Genomics, Inc. (NASDAQ:TXG) announced its earnings results on Thursday, November, 2nd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.06. The business earned $153.64 million during the quarter, compared to analyst estimates of $150.11 million. 10x Genomics had a negative trailing twelve-month return on equity of 24.24% and a negative net margin of 37.79%. What ETFs hold 10x Genomics' stock? ETFs with the largest weight of 10x Genomics (NASDAQ:TXG) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Fidelity Disruptive Medicine ETF (FMED), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), BNY Mellon Innovators ETF (BKIV), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and Principal Healthcare Innovators ETF (BTEC). What is Serge Saxonov's approval rating as 10x Genomics' CEO? 25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did 10x Genomics IPO? (TXG) raised $297 million in an initial public offering on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? 10x Genomics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (10.72%), Baillie Gifford & Co. (7.06%), Morgan Stanley (3.68%), Sands Capital Management LLC (3.37%), ARK Investment Management LLC (2.55%) and Invesco Ltd. (1.88%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:TXG) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.